Cancer vaccines 2003: Opening address

Cancer Immunity

Volumn 3, Issue , 2003, Pages 1-10

  Old, Lloyd J ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

Cancer immunosurveillance; Cancer vaccines; Clinical trials; Immunologic monitoring; Tumor antigens

Indexed keywords

BCG VACCINE; CANCER TESTIS ANTIGEN; CANCER VACCINE; CD4 ANTIGEN; DIFFERENTIATION ANTIGEN; EPITOPE; GLYCOPROTEIN GP 100; HEAT SHOCK PROTEIN; INTERLEUKIN 2 RECEPTOR; MELAN A; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; NY ESO 1 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANTIGEN EXPRESSION; BLADDER CANCER; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONFERENCE PAPER; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MOLECULAR CLONING; NONHUMAN; ONCOGENE NEU; T LYMPHOCYTE; VACCINE PRODUCTION;

AIDS VACCINES; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; NEOPLASMS;

EID: 3042755028     PISSN: 14249634     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (8)

1. Cui Z, Willingham MC, Hicks AM, Alexander-Miller MA, Howard TD, Hawkins GA, Miller MS, Weir HM, Du W, DeLong CJ. Spontaneous regression of advanced cancer: identification of a unique genetically determined, age-dependent trait in mice. Proc Natl Acad Sci USA 2003; 100: 6682-7. (PMID: 12724523)
2. Patard J, Moudouni S, Saint F, Rioux-Leclercq N, Manunta A, Guy L, Ballanger P, Lanson Y, Hajri M, Irani J, Guille F, Beurton D, Lobel B; Bernard Lobel and The members of the Groupe Necker. Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years. Urology 2001; 58: 551-6. (PMID: 11597537)
3. Nishikawa H, Kato T, Tanida K, Hiasa A, Tawara I, Ikeda H, Ikarashi Y, Wakasugi H, Kronenberg M, Nakayama T, Taniguchi M, Kuribayashi K, Old LJ, Shiku H. CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci USA 2003; 100: 10902-6. (PMID: 12947044)
4. Cancer Immunome Database. URL: http://www2.licr.org/CancerImmunomeDB
5. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002; 188: 22-32. (PMID: 12445278)
6. Old LJ. Cancer/testis (CT) antigens - a new link between gametogenesis and cancer. Cancer Immun 2001; 1: 1. (PMID: 12747762)
7. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-13. (PMID: 12529460)
8. Sato E, Jungbluth A, Ahn J, Qian F, Gnjatic S, Santiago D, Ambrosone C, Keitz B, Ritter G, Lele S, Chen YT, Old LJ, Odunsi K. Prognostic significance of tumor-infiltrating lymphocytes and CT antigen expression in epithelial ovarian cancer. Cancer Vaccines 2003 meeting; poster # P-45.